<DOC>
	<DOCNO>NCT01788033</DOCNO>
	<brief_summary>To assess effect treatment XOMA 052 beta-cell function insulin production subject well-controlled Type 1 diabetes . The safety , tolerability , pharmacokinetics ( PK ) XOMA 052 also assess .</brief_summary>
	<brief_title>Effects XOMA 052 Insulin Production Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Type 1 diabetes ( American Diabetes Association [ ADA ] criterion ) &gt; 2 year duration judge stable investigator No clinically significant change treatment regimen T1D ( define 20 % change ) 3 month prior Screening Age ≥ 18 year ≤ 55 year HbA1c &lt; 7.5 % previous two measurement include measurement take Screening ( measurement must occur within 6 month prior enrollment ) Positive glutamate decarboxylase65 ( GAD65 ) and/or IA2 autoantibody Bodymass index ( BMI ) &gt; 18 &lt; 28 kg/m2 Willingness maintain current doses/regimens vitamin dietary supplement end study For subject reproductive potential , willingness use contraceptive measure adequate prevent subject subject 's partner become pregnant study . Adequate contraceptive measure include hormonal method use two cycle prior Screening ( e.g. , oral contraceptive pill , contraceptive patch , contraceptive vaginal ring ) , double barrier method ( e.g. , contraceptive sponge , diaphragm use conjunction contraceptive foam jelly , condom use conjunction contraceptive foam jelly ) , intrauterine method ( IUD ) , sterilization ( e.g. , tubal ligation monogamous relationship vasectomize partner ) , abstinence . For female receive hormone replacement therapy ( include limit oral contraceptive ) , must stable regimen ≥ 6 month prior Screening . Hormone therapy must initiate study Signs current infection history infection 3 month prior Day 0 Known positive Hep B surface antigen ( HBsAg ) , Hep C virus ( HCV ) , HIV History tuberculosis ( TB ) positive PPD test . A subject positive PPD test complete course treatment tuberculosis , document vaccination tuberculosis , negative QuantiFERON®TB test result eligible . High sensitivity Creactive protein ( hsCRP ) &gt; 10 mg/L Presence foot , leg , decubitus ulcer Neutropenia Anemia Clinically significant kidney liver disease From 1 week prior Screening , use antiinflammatory therapy aspirin ≤ 100 mg/day 5 consecutive day treatment nonsteroidal antiinflammatory drug ( NSAIDs ) treatment acute illness Current immunosuppressive treatment document immunodeficiency History severe allergic anaphylactic reaction History asthma require systemic corticosteroid therapy Coronary intervention hospitalization cardiovascular condition within 12 month prior Day 0 Uncontrolled hypertension History congestive heart failure History coronary event within 12 month prior Screening Female subject pregnant , plan become pregnant course study , recently deliver ( within 3 month Screening ) , breastfeed History malignancy within 5 year prior study entry carcinoma situ cervix thyroid , adequately treat , nonmetastatic squamous basal cell carcinoma skin Receipt live ( attenuate ) vaccine within 3 month prior Screening Use investigational drug within 30 day prior enrollment within 5 halflives investigational drug , whichever longer Any condition , opinion investigator , would jeopardize subject 's safety follow exposure study drug Any condition ( e.g. , psychiatric illness ) situation may compromise ability subject give write informed consent , may put subject significant risk , may confound study result , may interfere significantly subject 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>